iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care
Key Highlights
- ➤$237.5 million cash paid for VitalConnect acquisition, plus up to 423,334 shares
- ➤Acquisition expands iRhythm’s cardiac monitoring platform across ambulatory, inpatient and hospital-to-home settings
- ➤Transaction expected to enhance iRhythm revenue growth rate beginning in 2027
- ➤Previously communicated 15% adjusted EBITDA margin target for 2027 preserved
- ➤Updated 2026 financial guidance, including VitalConnect, due November 5, 2026
Expert Statements
Quentin Blackford, President and Chief Executive Officer of iRhythm
“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform”
Quentin Blackford, President and Chief Executive Officer of iRhythm
“VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”
Peter Van Haur, Chief Executive Officer of VitalConnect
“Joining iRhythm creates an opportunity to extend the reach and impact of VitalConnect’s technology”
Peter Van Haur, Chief Executive Officer of VitalConnect
“By bringing together what our team has built with iRhythm’s scale, clinical expertise and customer reach, we believe we can accelerate the growth of our platform, expand access to our technology and create even greater value for clinicians and patients.”
* Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable market across the continuum of care. * iRhythm’s commercial scale, health system relationships, market access expertise, and integrated clinical service capabilities are expected to accelerate VitalConnect's growth and expand customer access. * Transaction is expected to enhance iRhythm's revenue growth rate beginning in 2027 while preserving iRhythm’s previously communicated 15% adjusted EBITDA margin target for 2027. SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
“Today marks an important milestone as iRhythm continues its evolution toward a broader cardiac monitoring and intelligence platform,” said Quentin Blackford, President and Chief Executive Officer of iRhythm. “VitalConnect brings complementary mobile cardiac telemetry (MCT), multi-vitals and monitoring capabilities to iRhythm’s established end-to-end cardiac monitoring service. Together, we can offer clinicians greater choice, serve more patients and customers across the continuum of care, and deepen customer relationships. We are pleased to welcome the VitalConnect team to iRhythm.”
Get started
Create a free account to read the full story.